The “holy grail” of ATMP-based treatments is to provide cures for some of the world’s most debilitating disease states, but for this to occur, a unified front is needed to democratize these therapies – collaboration from industry, academia, supply chain and, indeed, clinicians and hospitals is paramount to ensuring safe manufacturing and transit.